PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
3.02%
ROE exceeding 1.5x Medical - Pharmaceuticals median of 0.17%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
1.50%
Positive ROA while Medical - Pharmaceuticals median is negative. Philip Fisher would see if the firm has a stronger model than peers.
3.86%
Positive ROCE while Medical - Pharmaceuticals median is negative. Peter Lynch might see a relative advantage over the sector.
19.45%
Gross margin below 50% of Medical - Pharmaceuticals median of 41.49%. Jim Chanos would suspect flawed products or pricing.
3.72%
Margin of 3.72% while Medical - Pharmaceuticals median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
2.69%
Net margin of 2.69% while Medical - Pharmaceuticals is zero. Walter Schloss would examine if modest profitability can expand.